Introduction

If it is difficult to ascertain these data, other risk factors that should prompt the initiation of empiric anti-MRSA VAP therapy include a known history of MRSA colonization or infection, intravenous drug use, the presence of necrotizing pneumonia, an ill-appearing patient with a recent stay in a nursing home or skilled nursing facility, or a patient with a prolonged hospitalization with an ... ................
................